Unaddressed psychotropic medication orders and dose reduction recommendations
Summary
The facility failed to ensure that residents receiving psychotropic medications were not subjected to chemical restraints for 4 of 5 residents reviewed for unnecessary medications. The deficiency involved failure to limit PRN psychotropic orders to 14 days for residents receiving lorazepam, failure to attempt gradual dose reductions for residents receiving psychotropic medications, and failure to have physician responses documented for consultant pharmacist recommendations. The residents involved had diagnoses including dementia, anxiety, depression, cerebral infarction, hemiplegia, dysphagia, and chronic medical conditions, and several had severe or moderate cognitive impairment based on BIMS scores. Resident #11 had severe cognitive impairment and diagnoses including dementia with behaviors/agitation, major depressive disorder, and anxiety disorder. The resident had a PRN lorazepam order for 0.5 mg every 6 hours and received the medication during the month reviewed. The consultant pharmacist noted that PRN psychotropic medications are limited to an initial 14 days and require prescriber evaluation before extension, but there was no documentation that the physician addressed this recommendation. Resident #2 also had severe cognitive impairment and diagnoses including anxiety, depression, dementia, and chronic pain. The resident had a PRN lorazepam oral concentrate order for agitation and received the medication as ordered, but the consultant pharmacist recommendation regarding the 14-day limit and prescriber evaluation was not addressed. Resident #25 had moderate cognitive impairment and diagnoses including major depressive disorder, hypertension, venous thrombosis history, and congestive heart failure; the consultant pharmacist recommended gradual dose reductions for Zoloft and doxepin, but the physician did not address the recommendations. Resident #37 had moderate cognitive impairment and diagnoses including cerebral infarction, hemiplegia, nicotine dependence, anxiety disorder, hypertension, dysphagia, and depressive episodes; the consultant pharmacist requested dose reductions for buspirone, diazepam, and duloxetine, and requested a specific duration and stop date for Ambien and a CMS-approved diagnosis for Seroquel, but these recommendations were not addressed and the resident continued to receive the medications as ordered.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release August 26, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.